This webinar aims to review and discuss data for liquid biopsy-based assessments as endpoints of antitumour activity in clinical trials, understand the potential and limitations of liquid biopsy-based tumour genomic profiling for patient stratification and detection of predictive biomarkers of response to therapy, and to discuss how tumour heterogeneity and evolution assessed via liquid biopsy assays may improve prostate cancer treatment strategies.
The webinar will also offer the opportunity for real-time interaction between audience and experts.
Gerhardt Attard, Himisha Beltran
Welcome and Introduction, Prof. Alexander Wyatt, Vancouver Prostate Centre, BC Cancer, University of British Columbia, Vancouver, Canada
CtDNA Fraction and CTC count as Prognostic or Response Biomarkers in Prostate Cancer, Prof. Gerhardt Attard, Urological Cancer Research, University College London, London, UK
Liquid Biopsy Profiling for Advanced Prostate Cancer Stratification and Precision Oncology, Prof. Himisha Beltran, Division of Genitourinary Oncology and Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, US
Serial Liquid Biopsy to Reveal Prostate Cancer Evolution and Mechanisms of Drug Resistance, Prof. Alexander Wyatt, Vancouver Prostate Centre, BC Cancer, University of British Columbia, Vancouver, Canada
Closing Remarks, Prof. Alexander Wyatt, Vancouver Prostate Centre, BC Cancer, University of British Columbia, Vancouver, Canada
- Understand the principles of detection/quantification of ctDNA fraction and CTC count as prognostic or response biomarkers in prostate cancer
- Understand the potentials of liquid biopsy profiling for advanced prostate cancer stratification and precision oncology
- Understand potentials from a serial liquid biopsy to reveal prostate cancer evolution and mechanisms of drug resistance